Shuttle Pharmaceuticals announced the issuance of U.S. Patent No. 12,077,515, titled “Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease.” This patent was officially issued on September 3, 2024, further strengthening Shuttle Pharma’s intellectual property portfolio and supporting its ongoing efforts to develop novel therapeutics targeting histone deacetylase, HDAC, enzymes. The newly issued patent covers a series of selective HDAC inhibitors designed to modulate the expression of genes involved in cancer progression, immune responses, and other critical biological pathways. These inhibitors are being developed as potential treatments for a range of human diseases, including cancer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH:
- Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
- Shuttle Pharmaceuticals gets ODD for IPdR to treat brain tumors
- Shuttle Pharma Provides Second Quarter 2024 Corporate Update
- Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Shuttle Pharmaceuticals regains compliance with Nasdaq requirement